Filtered By:
Condition: Hypertension
Education: Study
Countries: Australia Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 49 results found since Jan 2013.

Development and validation of a dementia risk score in the UK Biobank and Whitehall II cohorts
Background Current dementia risk scores have had limited success in consistently identifying at-risk individuals across different ages and geographical locations. Objective We aimed to develop and validate a novel dementia risk score for a midlife UK population, using two cohorts: the UK Biobank, and UK Whitehall II study. Methods We divided the UK Biobank cohort into a training (n=176 611, 80%) and test sample (n=44 151, 20%) and used the Whitehall II cohort (n=2934) for external validation. We used the Cox LASSO regression to select the strongest predictors of incident dementia from 28 candidate predictors and then dev...
Source: Evidence-Based Mental Health - August 21, 2023 Category: Psychiatry & Psychology Authors: Anatürk, M., Patel, R., Ebmeier, K. P., Georgiopoulos, G., Newby, D., Topiwala, A., de Lange, A.-M. G., Cole, J. H., Jansen, M. G., Singh-Manoux, A., Kivimäki, M., Suri, S. Tags: Open access, Press releases Old age psychiatry Source Type: research

Older People With Atrial Fibrillation and Hypertension Are at Higher Risk of Poor Blood Pressure Control in Australian Primary Care
This study explored factors that influence BP control in AF patients with hypertension managed in Australian primary care, with a focus on older age.
Source: Heart, Lung and Circulation - July 1, 2023 Category: Cardiology Authors: R. Trivedi, T. Shaw, C. Chow, L. Laranjo Source Type: research

Sex differences in the association between stroke risk factors and pre-clinical predictors of stroke in the childhood determinants of Adult Health study
CONCLUSIONS: Smoking, SBP and glucose affect carotid structure and function more in women than men with some of this risk due to co-occurring risk factors.PMID:37391336 | DOI:10.1016/j.atherosclerosis.2023.06.077
Source: Atherosclerosis - June 30, 2023 Category: Cardiology Authors: Mohammad Shah Marie-Jeanne Buscot Jing Tian Hoang T Phan Thomas H Marwick Terence Dwyer Alison Venn Seana Gall Source Type: research

The 5 Best Ways to Control High Cholesterol, According to People With the Condition
There are a variety of factors that influence cardiovascular risk—but cholesterol is one of the first things that doctors pay attention to. Having high levels of low-density lipoprotein (LDL) cholesterol is “definitely a variable we try to manage, because it’s been shown to be problematic for heart health,” says Dr. Adriana Quinones-Camacho, a cardiologist at NYU Langone Health. Though it’s often called the “bad” kind of cholesterol, LDL cholesterol makes up most of your body’s cholesterol stores. That means it’s not a villain on its own, but when levels start creeping ...
Source: TIME: Health - January 18, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate heart health Source Type: news

Relationship Between MicroRNA Signature and Arterial Stiffness in Patients With Ischemic Stroke
CONCLUSIONS: The expression level of let-7i was independently related to arterial stiffness in patients with cerebral infarction, suggesting that it plays a pathophysiological role in atherosclerosis.PMID:36606643 | DOI:10.3988/jcn.2023.19.1.28
Source: Atherosclerosis - January 6, 2023 Category: Cardiology Authors: Sang-Jin Lee Jeong-Min Kim Eun Sun Lee Kwang-Yeol Park Hye Ryoun Kim Source Type: research

Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news